Biolabs' CONNECTED DIAGNOSTICS App anddecentralizedclinical trial platform integrates rapid diagnostic testing, artificial intelligence, and telehealth, all accessible from a smartphone
Biolabs International LLC, a healthcare innovation company based in San Diego, California, is transforming how diagnostics are delivered and accessed , both in the home and in clinical research. Through the rollout of its CONNECTED DIAGNOSTICS App anddecentralizedclinical trial platform, Biolabs is eliminating unnecessary doctor visits, reducing barriers to care, setting new standards for accessible, AI-powered healthcare and facilitating the FDA registration and approval process for future diagnostic tools.
https://mma.prnewswire.com/media/2402201/Biolabs_logo.jpg
At the center of this advancement is the integration of rapid diagnostic testing, artificial intelligence, and telehealth, all accessible from a smartphone or iPad. Consumers can now self-administer a SpeedySwab™ test at home, scan a QR codeon the SpeedySwab™ box and can be downloaded on both Apple and Google store, receive AI-interpreted results in minutes, and connect with healthcare professionals on-demand, all without leaving their home.
Click this link to the SpeedySwab™ App.
Less Waiting, More EmpowermentBiolabs' approach significantly reduces the need for in-person clinic visits. Instead of waiting days for appointments or exposing others in crowded waiting rooms, users can now test and receive care at home. The app includes step-by-step guidance, AI-driven result analysis, and the option to launch a telehealth consultation immediately if needed.
This real-time, remote care model not only alleviates pressure on critical healthcare infrastructure but also enhances accessibility for individuals in rural, underserved, or high-risk environments. By reducing overall healthcare costs and lessening the strain on the system during peak flu seasons or pandemics, Biolabs is facilitating the secure and reliable delivery of diagnostic results, whether administered at home, in-clinic, or via kiosk directly to EHRs, HIEs, and retail health ecosystems through its SAFE platform.
AI-Driven Accuracy and IntegrationThe CONNECTED DIAGNOSTICS App, developed in collaboration with SafeHealth Systems and the Mayo Clinic is not just a digital interface, it's an AI-powered diagnostic assistant. The platform uses proprietary algorithms to interpret lateral flow test results, minimizing human error and improving reliability for users.
All data is encrypted and HIPAA-compliant, with secure sharing options for healthcare providers, employers, or public health agencies. The app is also integrated with telehealth capabilities, enabling users to receive real-time medical advice and prescriptions based on their test results. Biolabs International is eliminating unnecessary doctor visits, reducing barriers to care, and setting new standards for accessible, AI-powered healthcare.
DecentralizedClinical Trial InnovationBeyond consumer testing, Biolabs is leading the charge in modernizing how clinical research is conducted. The decentralizedclinical trial (DCT) platform enables remote consent, test kit delivery, AI-based identity verification, and proctored testing sessions, all while reducing clinical study costs.
By digitizing the trial process, Biolabs aligns with the FDA's guidance on remote data collection and improves participant retention, compliance, and accuracy. Researchers benefit from faster recruitment, automated data capture, and seamless integration with EMRs and regulatory reporting systems.
Broad Retail and Public Safety PresenceBiolabs' SpeedySwab™ kits are now stocked nationwide at Walgreens, Kroger, and BevMo, making clinical-grade testing more accessible than ever. Assembled in the U.S., each kit is packaged with a QR-linked experience for digital onboarding, ensuring quality control and rapid scale-up during public health emergencies.
Powder TracerBiolabs International LLC announces the launch ofPowderTracer™, a rapid 7-panel surface drug detection kit paired with a proprietary AI- assisted app. Designed and manufactured in the USA, PowderTracer™ delivers forensic-grade results in under five minutes detecting fentanyl, carfentanil , xylazine, methamphetamine, cocaine, K2, and THC with exceptional speed and accuracy. Built for law enforcement, border control, corrections, and emergency responders, the system simplifies field testing and enhances accountability by automatically generating a digital report of the findings, complete with photo documentation. PowderTracer ™ ensures fast, accurate, and traceable detection empowering frontline teams with real-time, actionable intelligence.
Click link to Connect with PowderTracer App
The system's AI-assistedapp guides field responders through the testing process and instantly generates a printable digital report. By removing subjectivity and ensuring consistent documentation, PowderTracer™ empowers law enforcement and forensic teams to act decisively and defensibly in the field.
The Future of Diagnostics Is HereWhether empowering a parent to test their child for flu at home or enablingdecentralizedclinical trials or in field drug testing of all objects Biolabs is delivering a new approach, one that is agile, connected, and accessible from anywhere. The company plans to expand its platform into women's health, infectious disease, and chronic condition management and pet health.
Media Contact: Biolabs International LLCinfo@biolabsinternational.net sales@biolabsinternational.net 1-800-440-4580
https://mma.prnewswire.com/media/2749399/Biolabs_COMBO_01.jpg
https://mma.prnewswire.com/media/2749400/Biolabs_COVID19_1TEST_SEC_01.jpg
https://mma.prnewswire.com/media/2749401/Biolabs_COVID19_1TEST_SEC_02.jpg
https://mma.prnewswire.com/media/2749402/Biolabs_COVID19_1TEST_SEC_03.jpg
https://c212.net/c/img/favicon.png?sn=LA50347&sd=2025-08-19
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolabs-internationals-new-app-cuts-clinic-visits-expands-testing-access-302533802.html
SOURCE Biolabs International LLC
https://rt.newswire.ca/rt.gif?NewsItemId=LA50347&Transmission_Id=202508191403PR_NEWS_USPR_____LA50347&DateId=20250819